Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

600 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combining targeted and systematic prostate biopsy improves prostate cancer detection and correlation with the whole mount histopathology in biopsy naïve and previous negative biopsy patients.
Mischinger J, Schöllnast H, Zurl H, Geyer M, Fischereder K, Adelsmayr G, Igrec J, Fritz G, Merdzo-Hörmann M, Elstner J, Schmid J, Triebl A, Trimmel V, Reiter C, Steiner J, Rosenlechner D, Seles M, Pichler GP, Pichler M, Riedl J, Schöpfer-Schwab S, Strobl J, Hutterer GC, Zigeuner R, Pummer K, Augustin H, Ahyai S, Mannweiler S, Fuchsjäger M, Talakic E. Mischinger J, et al. Among authors: pichler gp, pichler m. Front Surg. 2022 Oct 6;9:1013389. doi: 10.3389/fsurg.2022.1013389. eCollection 2022. Front Surg. 2022. PMID: 36277287 Free PMC article.
Preoperative fibrinogen/CRP score predicts survival in upper urothelial tract carcinoma patients undergoing radical curative surgery.
Egger V, Hutterer GC, Mischinger J, Seles M, Pichler R, Mannweiler S, Huber K, Balihodzic A, Spiegelberg J, Bauernhofer T, Ahyai S, Zigeuner R, Pichler M, Barth DA. Egger V, et al. Among authors: pichler r, pichler m. World J Urol. 2023 May;41(5):1359-1364. doi: 10.1007/s00345-023-04379-y. Epub 2023 Apr 6. World J Urol. 2023. PMID: 37024555 Free PMC article.
MicroRNAs as regulators of tumor metabolism.
Ruggieri F, Jonas K, Ferracin M, Dengler M, Jӓger V, Pichler M. Ruggieri F, et al. Among authors: pichler m. Endocr Relat Cancer. 2023 Jul 18;30(8):e220267. doi: 10.1530/ERC-22-0267. Print 2023 Aug 1. Endocr Relat Cancer. 2023. PMID: 37224081 Review.
MiR-4649-5p acts as a tumor-suppressive microRNA in triple negative breast cancer by direct interaction with PIP5K1C, thereby potentiating growth-inhibitory effects of the AKT inhibitor capivasertib.
Jonas K, Prinz F, Ferracin M, Krajina K, Pasculli B, Deutsch A, Madl T, Rinner B, Slaby O, Klec C, Pichler M. Jonas K, et al. Among authors: pichler m. Breast Cancer Res. 2023 Oct 6;25(1):119. doi: 10.1186/s13058-023-01716-2. Breast Cancer Res. 2023. PMID: 37803350 Free PMC article.
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Santoni M, Buti S, Myint ZW, Maruzzo M, Iacovelli R, Pichler M, Kopecky J, Kucharz J, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Kopp RM, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Massari F, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Sunela K, Bassanelli M, Ortega C, Grillone F, Landmesser J, Milella M, Messina C, Küronya Z, Mosca A, Bhuva D, Santini D, Vau N, Morelli F, Incorvaia L, Rebuzzi SE, Roviello G, Soares A, Bisonni R, Bimbatti D, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Battelli N, Bracarda S, Porta C. Santoni M, et al. Among authors: pichler r, pichler m. Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21. Eur Urol Oncol. 2024. PMID: 37481365
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
Santoni M, Massari F, Myint ZW, Iacovelli R, Pichler M, Basso U, Kopecky J, Kucharz J, Buti S, Rizzo M, Galli L, Büttner T, De Giorgi U, Kanesvaran R, Fiala O, Grande E, Zucali PA, Fornarini G, Bourlon MT, Scagliarini S, Molina-Cerrillo J, Aurilio G, Matrana MR, Pichler R, Cattrini C, Büchler T, Seront E, Calabrò F, Pinto A, Berardi R, Zgura A, Mammone G, Ansari J, Atzori F, Chiari R, Bamias A, Caffo O, Procopio G, Bassanelli M, Merler S, Messina C, Küronya Z, Mosca A, Bhuva D, Vau N, Incorvaia L, Rebuzzi SE, Roviello G, Zabalza IO, Rizzo A, Mollica V, Sorgentoni G, Monteiro FSM, Montironi R, Battelli N, Porta C. Santoni M, et al. Among authors: pichler r, pichler m. Target Oncol. 2023 Jul;18(4):559-570. doi: 10.1007/s11523-023-00978-2. Epub 2023 Jun 27. Target Oncol. 2023. PMID: 37369815
Ouabain at nanomolar concentrations is cytotoxic for biliary tract cancer cells.
Mayr C, Kiesslich T, Bekric D, Beyreis M, Kittl M, Ablinger C, Neureiter E, Pichler M, Prinz F, Ritter M, Neureiter D, Jakab M, Dobias H. Mayr C, et al. Among authors: pichler m. PLoS One. 2023 Jun 30;18(6):e0287769. doi: 10.1371/journal.pone.0287769. eCollection 2023. PLoS One. 2023. PMID: 37390071 Free PMC article.
600 results